Education
About Us
Working with TipRanks
Follow Us
Agenus (AGEN)
NASDAQ:AGEN
AGEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.38 - $18.74
Previous CloseN/A
Volume199.21K
Average Volume (3M)1.20M
Market Cap
$154.36M
Enterprise Value$116.04M
Total Cash (Recent Filing)$40.44M
Total Debt (Recent Filing)$94.87M
Price to Earnings (P/E)―
Beta2.88
Next Earnings
Aug 07, 2025EPS Estimate
-0.99Last Dividend Ex-Date
Apr 26, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding27,416,850
10 Day Avg. Volume2,002,192
30 Day Avg. Volume1,195,500
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)-0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.39
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue0.20
Enterprise Value/Gross Profit4.68
Enterprise Value/Ebitda-0.29
Forecast
1Y Price Target
$13.00Price Target Upside151.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Agenus News
Bulls Say, Bears Say
Bulls Say
Capital InfusionThe partnership agreement with Zydus Lifesciences provides a significant cash infusion for Agenus, relieving near-term capital constraints.
Regulatory ProgressAgenus plans to re-engage with the FDA on potential pathway for approval of bot/bal in metastatic microsatellite stable colorectal cancer, aiming for a quicker path to market.
Strategic CollaborationThe strategic collaboration with Zydus is valued at up to $141M and aims to accelerate the clinical development of botensilimab and balstilimab while securing scaled manufacturing.
Bears Say
Analyst SentimentAnalyst remains Neutral until updates are provided on path to market and a better sense of if the FDA's advice has changed since last year.
Regulatory ChallengesAt last year’s meeting, the FDA recommended against accelerated approval filing and requested additional data to show that BOT/BAL could lead to a survival benefit.
Uncertainty In Development StrategyAgenus has not yet provided a strategy forward in neoadjuvant solid tumor development beyond ongoing ISTs, indicating a lack of clear future direction.
Ownership Overview
10.68% Insiders
15.05% Mutual Funds
2.59% Other Institutional Investors
63.21% Public Companies and Individual Investors
AGEN FAQ
What was Agenus’s price range in the past 12 months?
Agenus lowest stock price was $1.38 and its highest was $18.74 in the past 12 months.
What is Agenus’s market cap?
Agenus’s market cap is $154.36M.
When is Agenus’s upcoming earnings report date?
Agenus’s upcoming earnings report date is Aug 07, 2025 which is in 61 days.
How were Agenus’s earnings last quarter?
Agenus released its earnings results on May 12, 2025. The company reported -$1.03 earnings per share for the quarter, beating the consensus estimate of -$1.654 by $0.624.
Is Agenus overvalued?
According to Wall Street analysts Agenus’s price is currently Undervalued.
Does Agenus pay dividends?
Agenus pays a Notavailable dividend of $0.6 which represents an annual dividend yield of N/A. See more information on Agenus dividends here
What is Agenus’s EPS estimate?
Agenus’s EPS estimate is -0.99.
How many shares outstanding does Agenus have?
Agenus has 27,416,850 shares outstanding.
What happened to Agenus’s price movement after its last earnings report?
Agenus reported an EPS of -$1.03 in its last earnings report, beating expectations of -$1.654. Following the earnings report the stock price went up 20.275%.
Which hedge fund is a major shareholder of Agenus?
Among the largest hedge funds holding Agenus’s share is Oracle Investment Management Inc. It holds Agenus’s shares valued at 0.
Agenus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.00 (151.94% Upside)
$13.00 (151.94% Upside)
Blogger Sentiment
Neutral
AGEN Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 127.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.4%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-70.63%
12-Months-Change
Fundamentals
Return on Equity
260.68%
Trailing 12-Months
Asset Growth
-21.97%
Trailing 12-Months
Company Description
Agenus
Agenus Inc. (AGEN) is a biotechnology company focused on the discovery and development of therapies that harness the body's immune system to combat cancer. The company operates in the healthcare sector, specifically in immuno-oncology, and offers a range of therapeutic antibodies, vaccines, and adjuvants designed to enhance immune response against tumors. Agenus is committed to developing innovative treatments that address unmet medical needs in oncology.
AGEN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented significant advancements in leadership, operational efficiency, and promising clinical data for BOT/BAL, despite ongoing financial losses and cash balance concerns. The strategic transactions and new data provide optimism for future growth and regulatory success. However, past regulatory challenges and financial constraints remain points of concern.Read More>AGEN Stock 12 Month Forecast
Average Price Target
$13.00
▲(151.94%Upside)
Technical Analysis
Cyclacel Pharmaceuticals
―
Fortress Biotech
―
Outlook Therapeutics
―
Quince Therapeutics
―